Renal Dysfunction in Patients with Beta-Thalassemia Major Receiving Iron Chelation Therapy either with Deferoxamine and Deferiprone or with Deferasirox

Publisher： Karger

E-ISSN： 1421-9662|123|3|148-152

ISSN： 0001-5792

Source： Acta Haematologica, Vol.123, Iss.3, 2010-02, pp. : 148-152

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Deferiprone Chelation Therapy for Thalassemia Major

By  

Acta Haematologica, Vol. 122, Iss. 2-3, 2009-11 ,pp. : 155-164

Karger

Access to resources Recommend Favorite

Paradoxically Increased Ferritin Level in a Beta-Thalassemia Major Patient following the Start of Deferasirox Chelation Therapy

By  

Acta Haematologica, Vol. 123, Iss. 2, 2010-01 ,pp. : 117-120

Karger

Access to resources Recommend Favorite

Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 2, 2015-02 ,pp. : 91-96

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of the Incidence of Sensorineural Hearing Loss in Beta-Thalassemia major Patients under Regular Chelation Therapy with Desferrioxamine

By  

Acta Haematologica, Vol. 108, Iss. 2, 2002-08 ,pp. : 79-83

Karger

Access to resources Recommend Favorite

The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β‐thalassemia major: A prospective, single center, open‐label study

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 9, 2015-09 ,pp. : 1592-1596

John Wiley & Sons Inc

Access to resources Recommend Favorite